Although EGFR and HER2-targeted therapy has substantial activity in EGFR and HER2-overexpressing malignancies, respectively, therapeutic resistance and progression eventually develops in responders with metastatic disease who remain on therapy. This evidence concerns the gene ERBB2 and metastatic neoplasm.